Tirzepatide (Zepbound, Mounjaro) is a dual-agonist GLP-1 medication. It works like a GLP-1 agonist, but also targets a hormone called glucose-dependent insulinotropic polypeptide (GIP) to “help break ...

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss. Headlines often describe them as ...

By Vijay Kumar Malesu Emerging evidence suggests that microbial metabolites not only regulate endogenous GLP-1 secretion but may also influence therapeutic response to GLP-1 receptor agonists, raising ...

Researchers have discovered that drugs like Ozempic for diabetes and obesity also improve alcohol use disorders and other ...

The following slide deck was published by Structure Therapeutics Inc. in conjunction with this event.

By Tarun Sai Lomte Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks, and what clinicians should monitor long term. Review: ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fewer adolescents in the GLP-1 receptor agonist group vs ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

Eli Lilly and Company LLY is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, supported by the strong success of its GLP-1–based therapies — Mounjaro for ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...